Accès ouvert
2026
preprint
OpenAlex
Martina Antoniolli, Llucia Albertí Servera, Kerstin Paetzold, Stephan Schmeing et autres
Abstract Background Single-cell RNA sequencing (scRNA-seq) has become essential for understanding disease biology, yet its application in clinical trials is often limited by logistical challenges associated with the handling of biospecimens. Newly developed protocols aim to address these limitations by enabling profiling …
ch
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Moritz Rapp, Harald Duerr, Gabriel Schnetzler, Davide Bertoldo et autres
Abstract Interferon alpha (IFNa) is recognized for its potential in cancer immunotherapy by activating immune responses against tumor cells. However, untargeted IFNa's application is limited by systemic toxicity and non-specific activity, affecting both tumor and healthy tissues and resulting in undesirable side …
ch, gb, de
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Giovanna Fiore, Wolfgang Weckwarth, Kerstin Paetzold, Llucia Albertí Servera et autres
Introduction Plasmacytoid dendritic cells (pDCs) are capable of triggering broad immune responses, yet, their scarcity in blood coupled to their reduced functionality in cancer, makes their therapeutic use for in situ activation or vaccination challenging. Methods We designed an in vitro differentiation …
de, ch
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Angelika J. Fischbeck, Svenja Ruehland, Andreas Ettinger, Kerstin Paetzold et autres
Adoptive T cell therapy (ACT) is highly effective in the treatment of hematologic malignancies, but shows limited success in solid tumors. Inactivation of T cells in the tumor milieu is a major hurdle to a wider application of ACT. Cytotoxicity is the …
de
(code pays fourni par la source)